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Purpose: Several studies have compared the effects of coronary stenting and coro-
nary-artery bypass grafting (CABG) on left main coronary artery (LMCA) disease. 
However, there are limited data on the long-term outcomes of these two interven-
tions in diabetic patients. Materials and Methods: We evaluated 56 patients with 
LMCA stenosis who underwent drug-eluting stent (DES) implantation and 116 pa-
tients who underwent CABG in a single hospital in China between January 2004 
and December 2006. We compared long-term major adverse cardiac events (death; a 
“serious outcome” composite of death, myocardial infarction, or stroke; and target-
vessel revascularization). Results: In-hospital (30-day) mortality was 0% for the 
DES group and 3.4% for the CABG group (p=0.31). There was no difference be-
tween the two groups in terms of risk of death [hazard ratio for stenting group, 0.49; 
95% confidence interval (CI), 0.13-1.63; p=0.55] or risk of serious outcome (hazard 
ratio for DES group, 1.11; 95% CI, 0.39-1.45; p=0.47). The target-vessel revascular-
ization rate was higher in the DES group than in the CABG group (hazard ratio, 
3.67; 95% CI, 1.24-11.06; p=0.018). Conclusion: In this cohort of diabetic patients 
with LMCA stenosis, there was no difference in composite endpoints between pa-
tients receiving DESs and those undergoing CABG. However, stenting was associat-
ed with higher rates of target-vessel revascularization than CABG. DES implantation 
in diabetic patients with LMCA disease was found to be at least as safe as CABG.
Key Words:    Left main coronary artery disease, coronary intervention, drug-elut-
ing stent, coronary-artery bypass grafting, diabetes mellitus
INTRODUCTION
As known, coronary-artery bypass grafting (CABG) has been considered standard 
therapy for patients with left main coronary artery disease and is recommended by 
current practice guidelines.1,2 However, these guidelines have been challenged by 
the widespread use of coronary stents in combination with improved antiplatelet Xiaoxiao Zhao, et al.
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Revascularization procedure
Patients underwent PCI instead of CABG due to their own 
or their physician’s preference or the high risk associated 
with CABG. Previous studies described about the methods 
of stent implantation for patients with LMCA disease.12,13 
Standard interventional techniques were processed for all 
procedures. According to the operators’ discretion, the use 
of pre-dilation, an intra-aortic balloon pump, or intravascu-
lar ultrasound and the choice of the specific type of DES 
were applied for each patient treatment. Periprocedurla an-
ticoagulation and antiplatelet therapy followed standard 
regimens. All patients undergoing stenting were prescribed 
clopidogrel for at least 12 months. Treatment beyond this 
duration was administered at the discretion of the physician 
(clopidogrel 79.2% at the end of follow-up in the PCI group). 
Aspirin was prescribed indefinitely for all patients who un-
derwent either PCI with DES or CABG treatment. Surgical 
revascularization was performed with the use of standard 
bypass techniques.14 Whenever possible, the internal tho-
racic artery was used preferentially for revascularization of 
the left anterior descending artery. Complete revasculariza-
tion was performed when possible with arterial conduits or 
saphenous vein grafts. A recognized standard of post-inter-
ventional care was recommended to the patients.15 Other 
procedural details are given in Table 1.
Follow-up, end points, and definitions
Clinical follow-up after PCI with DES and after CABG was 
stopped in March 2008, and major adverse cardiac events 
(MACE) that occurred during the follow-up period were 
studied. During the 30 days of in-hospital follow-up, renal 
events were also evaluated by biological analysis and calcu-
lated for major adverse cardiac cerebrovascular and renal 
events (MACCRE). Routine angiographic follow-up was 
recommended by the operators in PCI-group patients (22/56, 
39.3%) 6 to 12 months after the procedure. However, pa-
tients who were at high risk of procedural complications of 
angiography and had no symptoms or signs of ischemia, as 
well as patients who declined to comply with this recom-
mendation, did not undergo routine follow-up angiography. 
For CABG-group patients, angiographic follow-up was rec-
ommended only if there were ischemic symptoms or signs 
during follow-up (29/116, 25.0%). This is consistent with 
previous studies in which a low threshold for control coro-
nary angiography was maintained.16 
The endpoints of the study were death, the “serious out-
comes” composite (death, Q-wave myocardial infarction, or 
treatment and by the recent introduction of drug-eluting stents 
(DESs), which virtually eliminate the recurrence of acute 
coronary occlusion and also limit the occurrence of resteno-
sis.3,4 Percutaneous coronary intervention (PCI) is therefore 
being used increasingly in patients with left main coronary 
artery (LMCA) stenosis.5
In patients with coronary artery diseases, diabetes melli-
tus (DM) increases the risk of cardiac mortality approxi-
mately two- to four-fold.6,7 Although the acute outcomes af-
ter PCI are similar in patients with and without diabetes, 
because of excessive neointimal proliferation, diabetic pa-
tients have higher rates of restenosis and repeat revascular-
ization after PCI with or without stenting.8,9 Preliminary re-
sults from registries show that the implantation of DESs for 
unprotected LMCA disease in patients without diabetes is a 
feasible and safe approach.10 However, until now, no study 
has analyzed the treatment of LMCA lesions with PCI ver-
sus CABG in diabetic patients. The purpose of this study 
was to compare treatment of LMCA lesions with PCI and 
DES implantation versus surgical revascularization in pa-
tients with DM during their hospital stay (30 days) and 
long-term follow-up.
MATERIALS AND METHODS
Study population
All diabetic patients with LMCA disease treated with PCI 
with DES implantation or CABG between January 2004 
and December 2006 at Beijing’s Anzhen Hospital (Capital 
University of Medical Sciences, Beijing, China) were con-
sidered for inclusion in this study. In all cases, the selected 
revascularization approach appeared to be suitable for guar-
anteeing complete revascularization. We excluded patients 
who had undergone previous CABG or who underwent 
concomitant valvular or aortic surgery. We also excluded 
those who had primary cardiomyopathy or myocardial in-
farction (MI) with ST-segment elevation, or who presented 
with cardiogenic shock. During the same period, one of the 
patients who underwent PCI received a bare-metal stent 
and was therefore excluded from the study. DM was diag-
nosed on the basis of a history of using glucose-lowering 
medications or insulin, or a fasting plasma glucose concen-
tration of ≥126 mg/mL.11 All patients were considered to 
have type 2 DM. The study protocol was approved by the 
appropriate local institutional ethics committee, and written 
informed consent was obtained from all patients.DES vs. CABG for Diabetic Patients with LMCA Disease
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ative-risk evaluation (Ontario score, available at http//www.
sfar.org/scores2/ontario2.htm) was used to stratify the risk 
of death during hospitalization in patients undergoing cardi-
ac surgery.17 Relevant factors that contributed to the Ontario 
score calculation include age, sex, ejection fraction, urgen-
cy of surgery, type of surgery, and repeat operation.
Statistical analysis
Data are presented as mean±standard deviation (SD). We 
compared the baseline covariates between the DES and 
CABG groups. Comparisons of the continuous baseline char-
acteristics were made using an unpaired t-test. Comparisons 
of categorical baseline characteristics were made using χ2 
tests. Statistical significance and the effects of both thera-
pies on the outcomes of in-hospital (up to 30 days) or long-
term follow-up were estimated. The Kaplan-Meier method 
stroke), and target-vessel revascularization (TVR). Clinical 
events were assessed annually by mail and/or telephone 
contact with the patients. The medical records of those pa-
tients who reported events were collected and the events 
adjudicated by the patient’s physician. Death was defined 
as death from any cause. Q-wave MI was defined as docu-
mentation of a new abnormal Q wave after the index treat-
ment. Stroke, as indicated by neurologic deficits, was con-
firmed by a neurologist on the basis of imaging studies. TVR 
was defined as repeat revascularization of the treated ves-
sel, including any segments of the left anterior descending 
artery and the left circumflex artery. Both PCI with DES 
and repeat CABG were judged as revascularization.
Ontario score calculation
The Ontario Province Risk system for cardiac surgery oper-
Table 1. Procedural Characteristics of Patients Treated with CABG and PCI
CABG (n=116)
    Off pump   108/115 (93.9%)
    Unprotected LMCA (% of patients)          166 (100%)
    Grafts per patient (number)           3.0±0.8 
        Venous grafts (% of patients)            20 (17.4)
        Artery grafts (% of patients)            96 (82.8)
    Left anterior descending artery revascularization (% of patients)          115 (99.1)
    Requirement for permanent pacemaker (% of patients)              3 (2.6)
    Support of intro-aortic balloon pump (% of patients)              4 (3.4)
    Salvage (% of patients)              5 (4.3)
    Ventricular tachycardia and fibrillation (% of patients)              3 (2.6)
    Cases in 2004/2005/2006 (% of patients) 29/37/50 (25.0/31.9/43.1)
PCI (n=56)
    Stent types
        Cypher-stent (% of patients)            53 (94.6)
        Endeavor-stent (% of patients)              3 (5.4)
    Total number of stents in LMCA lesions           2.3±0.2
    Total length of stents in LMCA lesions         27.8±27.1
    Total number of stents in a patients           2.8±1.6
    Maximal stent implantation pressure, atm         17.0±1.6
    Support of intro-aortic balloon pump (% of patients)              0 (0)
    Use of glycoprotein IIb/IIa inhibitor (% of patients)              9 (16.1)
    Requirement for permanent pacemaker (% of patients)              0 (0)
    Distal bifurcation-lesion (% of patients)            42 (75.0)
    Bifurcation stenting technology            40 (71.4)
        Single stenting (% of patients)            33 (58.9)
        Crush (% of patients)              0 (0)
        T stenting (% of patients)              4 (7.1%)
        Kissing stenting              4 (7.1%)
    Salvage (% of patients)              1 (1.8)
    Ventricular tachycardia and fibrillation (% of patients)              0 (0)
    Cases in 2004/2005/2006 (% of patients)   8/23/25 (14.3/41.1/44.6)
PCI, percutaneous cardiac intervention; CABG, coronary-artery bypass grafting; LMCA, left main coronary artery disease. 
Percentages may not total 100 because of rounding.Xiaoxiao Zhao, et al.
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cantly more likely to have had previous coronary bypass 
grafting than those receiving CABG (p=0.005). The PCI 
group included a significantly larger number of poorly con-
trolled diabetic patients (hemoglobin A1c, 8.1%±2.0% vs. 
7.0%±1.7%, p=0.016) (Table 2). Patients undergoing CABG 
had significantly lower ejection fractions (p=0.010) and On-
tario scores (p=0.04), and had significantly more instances 
of double- or quadruple-vessel disease and involvement of 
the right coronary artery (p<0.05). There was no significant 
difference in the proportion of patients in the two groups re-
ceiving insulin treatment (39.3% for the PCI group and 
38.8% for the CABG group, p=0.950). There were no sig-
nificant differences in any other preoperative characteristics 
between the PCI and CABG groups (p>0.05) (Table 2).
In-hospital events
The rates of MACCRE and acute MI (AMI) were signifi-
cantly higher in the CABG group (31.0% and 29.3%, re-
spectively) than in the PCI group (both 8.9%, p<0.001) 
(Table 3), during the in-hospital (up to 30-day) follow-up 
period. In the CABG group, in-hospital cardiac and stroke 
death occurred in four patients with acute coronary syn-
drome. One patient, who underwent concomitant pericardi-
al cystectomy, died from low cardiac output syndrome; two 
patients died from fatal AMI involving postoperative stroke; 
and one died from cardiac tamponade. The rates of cardiac 
tamponade, acute heart failure, permanent pacemaker im-
plantation, ventricular tachycardia and fibrillation, postop-
erative pneumothorax, shock, dialysis requirement, repeat 
thoracotomy for bleeding or suppuration, and vascular he-
matoma requiring repair were higher in the CABG group, 
but the differences between the two groups were not signif-
icant (Table 3). The duration of the post-procedural hospital 
stay was significantly longer in the CABG group than in 
the PCI group (p<0.001) (Table 3).
Long-term outcomes
The median follow-up was 28.5 months (interquartile range, 
18.5-29.5) in the PCI group and 28.4 months (17.9-38.9) in 
the CABG group (Table 4). Complete follow-up data for ma-
jor clinical events were obtained in 97.4% of the subjects 
overall (98.2% for the PCI group and 96.6% for the CABG 
group). During follow-up, 10 patients (6.1%) died; seven of 
these (one from the PCI group and six from the CABG 
group) died of cardiovascular causes. Twelve (7.0%) patients 
(14.5% in the PCI group and 3.7% in the CABG group, 
p=0.022) underwent TVR. The incidence rates of MACE 
was used to estimate the incidence of the clinical endpoints, 
death (overall survival), the “serious outcomes” composite 
(death, MI or stroke), and TVR, during the follow-up period. 
The Log-rank test was used to compare the Kaplan-Meier 
results. 
Multivariable analysis was performed using Cox propor-
tional hazards models adjusted for age, sex, body mass index 
(BMI), left ventricular ejection fraction, and Ontario scores.18 
Cox proportional hazard regression analysis was performed 
to calculate the hazard ratios and 95% confidence intervals 
(CIs) for the clinical outcomes.
A p-value of <0.05 was considered to indicate statistical 
significance. Data processing and statistical analysis was 
performed using the SPSS 13.0 statistical program (SPSS 
Inc., Chicago, IL, USA).
RESULTS
 
Baseline characteristics
Between January 2004 and December 2006, 172 patients 
with LMCA disease met the criteria for inclusion. Fifty-six 
of these patients received PCI with DES and 116 received 
CABG. A total of 168 patients (97.7%: 52 DES, 116 CABG) 
had unprotected LMCA disease.
In the DES group, 53 patients received rapamycin-eluting 
stents (94.6%) and three received zotarolimus-eluting stents 
(5.4%). The mean (±SD) total length of stents was 27.8±27.1 
mm, the total stent diameter was 3.4±0.6 mm, and the maxi-
mum stent implantation pressure was 17.0±1.6 atm. The 
mean total number of stents implanted in a patient (includ-
ing left and other vessels) was 2.8±1.6.
In the CABG group, 108 patients (93.1%) underwent off-
pump surgery. All of them received at least one arterial con-
duit, which was used in 115 of the patients (99.1%) towards 
the revascularization of the left anterior descending artery. 
One patient underwent concomitant left ventricular aneu-
rysmectomy and one underwent pericardial cystectomy. 
The mean number of grafts used was 3.0±0.8 (17.2% ve-
nous and 82.8% arterial).
The baseline characteristics of the study patients in each 
group are shown in Table 1. The numbers of patients in the 
two groups were well balanced with regard to most of the 
baseline demographic and clinical characteristics. Patients 
undergoing PCI had a significantly higher prevalence of 
family history of hypertension and of diabetic, coronary ar-
tery, and cerebral disease (p<0.001); they were also signifi-DES vs. CABG for Diabetic Patients with LMCA Disease
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difference between the PCI and CABG groups in terms of 
risk of death (hazard ratio for PCI group, 1.33; 95% CI, 
0.68-2.59; p=0.27) or risk of serious outcome (hazard ratio 
for PCI group, 1.37; 95% CI, 0.75-2.67; p=0.59). The rate 
of TVR was significantly higher in the PCI group than in 
and AMI tended to be greater in the PCI group (23.6% and 
10.9%, respectively) than in the CABG group (13.0% and 
8.3%, p>0.05), and the rate of cerebrovascular events tend-
ed to be greater in the CABG group (5.6%) than in the PCI 
group (0%, p=0.098) (Table 4). There was no significant 
Table 2. Baseline Patient Characteristics
Variable PCI (n=56) CABG (n=116) p value
Demographic characteristics
    Age (yrs) 51.4-61.5  54.8-72.0 0.353
    Female sex (% of patients) 15 (26.8)   33 (28.4) 0.820
    BMI ≥28 (% of patients) 14 (25.0)   18 (15.8) 0.134
Cardiac or coexisting conditions
    Family history 23 (41.1)   12 (10.3) 0.000
    Non-smoking (% of patients) 28 (50.0)   65 (56.5) 0.457
    Hypertension (% of patients) 32 (57.1)   60 (51.7) 0.504
    Hypercholesterolemia (% of patients) 25 (44.6)   49 (42.4) 0.537
    Previous coronary angioplasty (% of patients)   8 (14.3)     9 (7.8) 0.179
    Previous coronary artery bypass graft (% of patients)   6 (10.7)     1 (0.9) 0.005
    Acute myocardial infarction <1 month (% of patients)   7 (12.5)   27 (23.3) 0.096
    Previous myocardial infarction (% of patients) 14 (25)   26 (22.4) 0.707
    Pulmonary artery hypertension (% of patients)   2 (3.6)     7 (6.0) 0.720
    Cerebrovascular disease (% of patients)   8 (14.3)   25 (21.6) 0.257
    Thyroid disease (% of patients)   3 (5.4)     2 (1.7) 0.331
    Ejection fraction (%) 0.010
      Median 64.2 59.7
      Interquartile range 54.2-74.2 49.2-70.2
    Arrhythmia (% of patients)    5 (8.9)     9 (7.8) 0.773
    Unstable angina (% of patients) 46 (82.1)   89 (76.7) 0.418
    Ontario score 2.6-3.2 1.9.1-2.5 0.049
    Ontario score ≥6 (% of patients) 11/52 (21.2) 7/115 (6.1) 0.006
Biological parameters
    Creatinine >1.2 mg/dL (% of patients)   7 (12.5)   15 (12.9) 0.937
    Fasting blood glucose (mmol/L) 4.6-10.4   4.9-9.9 0.927
    Hemoglobin A1c (%) 6.1-10.1   5.3-8.7 0.016
Diabetic therapy
     Oral hypoglycemic therapy (% of patients) 24 (42.9)   59 (50.9) 0.119
     Insulin therapy (% of patients) 22 (39.3)   45 (38.8) 0.950
Angiographic characteristics
    Involved location (% of patients)
        Distal bifurcation 42 (75.0)   88 (75.9) 0.899
        Total occlusion lesion 16 (28.6)   38 (32.8) 0.579
    Extent of vessel disease (% of patients)
    Left main only   2 (3.6)     1 (0.9) 0.248
    Left main plus single-vessel disease 12 (21.4)     6 (5.2) 0.001
    Left main plus double-vessel disease 16 (28.6)   24 (20.7) 0.252
    Left main plus triple-vessel disease 26 (46.4)   85 (73.3) 0.001
    Right coronary artery disease (% of patients) 32 (57.1) 101 (87.1) 0.000
PCI, percutaneous cardiac intervention; CABG, coronary-artery bypass grafting. 
Percentages may not total 100 because of rounding. Data are shown as mean±SD for continuous variables and absolute numbers (per-
centages) for dichotomous variables. 
P values are based on the unpaired t-test for continuous variables and on the χ
2 tests for categorical variables.Xiaoxiao Zhao, et al.
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Table 3. In-Hospital Events
Event or variable PCI (n=56) CABG (n=116) p value
Major adverse cardiac cerebrovascular and renal events 
  (% of patients)    5 (8.9) 36 (31.0) 0.001
Death (% of patients) 0 (0) 4 (3.4) 0.305
Cardiac tamponade (% of patients) 0 (0) 1 (0.9) 1.00
Acute myocardial infarction (% of patients)    5 (8.9) 34 (29.3) 0.003
    Non-ST-segment elevation myocardial infarction 
      (% of infarction patients)   1 (20)   5 (14.7) 0.408
Acute left heart failure (% of patients) 0 (0) 2 (1.7) 0.819
Requirement for permanent pacemaker (% of patients) 0 (0) 2 (1.7) 0.819
Ventricular tachycardia and fibrillation (% of patients) 0 (0) 1 (0.9) 1.00
Pleural effusion (medium or more volume) (% of patients) 0 (0) 10 (8.6) 0.032
Postoperative pneumothorax (% of patients) 0 (0) 3 (2.6) 0.552
Shock (% of patients)    1 (1.8) 4 (3.4) 0.901
Requiring dialysis (% of patients) 0 (0) 3 (2.6) 0.552
Repeat thoracotomy for bleeding or suppuration 0 (0) 5 (4.3) 0.175
Repeat surgery for bleeding (% of patients) 0 (0) 1 (0.9) 1.00
Vascular hematoma requiring vascular repair (% of patients) 0 (0) 1 (0.9) 1.00
Postoperative creatinine (Cr >1.5 mg/dL) 0 (0) 14 (12.1) 0.005
In-hospital length of stay (days) 9.0-13.8 20-27 0.000
PCI, percutaneous coronary intervention; CABG, coronary-artery bypass grafting. 
Percentages may not total 100 because of rounding. P values are based on the unpaired t-test for continuous variables and on the χ
2 
tests for categorical variables.
Table 4. Follow-Up Outcomes
Event or variable PCI (n=55) CABG (n=108) p value
Followed-up cases (% of patients) 55 (98.2) 108 (96.4) 0.666
Follow-up period (months, mean±SD) 28.5±10.0 28.4±10.5 0.328
Major adverse cardiac events (% of patients) 13 (23.6) 14 (13.0) 0.083
Death (% of patients) 3 (5.5) 7 (6.5) 0.995
Acute myocardial infarction (% of patients)   6 (10.9) 9 (8.3) 0.591
Target-vessel revascularization (% of patients)   8 (14.5) 4 (3.7) 0.022
Cerebrovascular events 0 (0) 6 (5.6) 0.098
PCI, percutaneous coronary intervention; CABG, coronary-artery bypass grafting. 
Percentages may not total 100 because of rounding. Data are shown as mean±SD for continuous variables and absolute numbers 
(percentages) for dichotomous variables. P values are based on unpaired t-tests for continuous variables and on χ
2 tests for categorical 
variables. Data are shown as mean±SD for continuous variables and absolute numbers (percentages) for dichotomous variables.
Table 5. Hazard Ratios for Clinical Outcomes after Stenting as Compared to after CABG
Outcome Overall cohort (n=163) 
Hazard ratio (95% CI) p value
Death
    Unadjusted 1.33 (0.68-2.59) 0.266
    Adjusted (age/sex/BMI/EF/ONTARIO score) 0.51 (0.13-1.63) 0.551
Composite outcome of death, MI, and stroke
    Unadjusted 1.37 (0.75-2.67) 0.591
    Adjusted (age/sex/BMI/EF/ONTARIO score) 1.11 (0.39-1.45) 0.470
Target-vessel revascularization
    Unadjusted   4.89 (1.78-13.02) 0.000
    Adjusted (age/sex/BMI/EF/ONTARIO score)   4.27 (1.24-11.06) 0.018
CABG, coronary-artery bypass grafting; MI, myocardial infarction; BMI, body mass index; CI, confidence interval. 
Values in parentheses are 95% CIs. CIs were estimated from Cox proportional-hazard regression with or without covariate adjustment.DES vs. CABG for Diabetic Patients with LMCA Disease
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hand, the rate of statins-treatment tended to be higher for 
the PCI group (51.2%) than for the CABG group (39.8%, 
p=0.39), and the rate of clopitogrel treatment was signifi-
cantly higher for the PCI group (79.2%) than for the CABG 
group (17.8%, p<0.001).
DISCUSSION
   
During the in-hospital (up to 30-day) follow-up, DES im-
plantation for diabetic patients with LMCA lesions was 
shown to be safe and was associated with a low rate of in-
hospital events (including MACCER and AMI). Our long-
term observations showed that the risks of death and serious 
outcomes (death, Q-wave MI, or stroke) were similar be-
tween the PCI and CABG groups. In contrast, the rate of 
TVR was significantly higher in the PCI group than in the 
CABG group.
Recent observational studies have reported that patients 
undergoing CABG have a significantly higher 30-day mor-
tality rate than those receiving PCI.19,20 Our observations 
here showed that the patients in the CABG group tended to 
have higher rates of MACCRE and AMI than CABG pa-
tients. Ninety-four percent of the patients in our CABG 
group were found to have coronary stenosis involving more 
than one vessel in addition to the LMCA segment (p<0.05 
v. PCI group), and the CABG group was found to have sig-
nificantly lower Ontario scores and ejection fractions; these 
results were similar to those of previous studies.19-21 It is like-
ly that the patients who underwent PCI were those for whom 
the surgical risk was considered prohibitive, or those who 
were candidates for CABG but in whom PCI was consid-
ered feasible and relatively low-risk. Differences in the clini-
cal baseline demographics as well as the extent of coronary 
stenosis might have caused the greater proportion of in-hos-
pital events in the CABG group.
The assumption that CABG surgery is the best therapy 
for unprotected LMCA stenosis is based on the results of 
many historical studies performed two decades ago22 and 
on the disappointing results registered in early experience 
with PCI.23,24 Another large observational study, published 
before the development of the DES, suggested that patients 
with LMCA disease did significantly better with CABG 
than with PCI.25 Although this was a risk-adjusted analysis, 
patient-selection factors probably influenced the results. In 
contrast, favorable initial outcomes after LMCA interven-
tion using DESs have been reported in select low-risk pa-
the CABG group (hazard ratio, 4.89; 95% CI, 1.78-13.02; 
p<0.001). Following adjustment for age, sex, BMI, EF, and 
Ontario score, there was still no significant difference be-
tween the PCI and CABG groups in terms of risk of death 
(hazard ratio for PCI group, 0.49; 95% CI, 0.13-1.63; 
p=0.55) (Fig. 1A, Table 5) or risk of serious outcome (hazard 
ratio for PCI group, 1.11; 95% CI, 0.39-1.45; p=0.47) (Fig. 
1B, Table 5). The rate of TVR was still significantly higher in 
the PCI group than in the CABG group (hazard ratio, 3.67; 
95% CI, 1.24-11.06; p=0.018) (Fig. 1C, Table 5). On other 
Fig. 1. Kaplan-Meier curves of the PCI (n=56) and the CABG (n=116) groups 
for death, composite risk of serious outcomes, and the rate of target-vessel 
revascularization (TVR). There were no differences in death and composite 
risk between the two groups (A and B), whereas the rate of TVR was high-
er in the PCI group than in the CABG group (C). PCI, percutaneous coro-
nary intervention; CABG, coronary-artery bypass grafting; MI, myocardial 
infarction. 
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cardiac and cerebrovascular event rate is higher among dia-
betic patients with left main and/or 3-vessel disease treated 
with paclitaxel-eluting stents compared with CABG, due to 
the increase in repeat revascularization.39 We observed no 
increases in the risk of death or of composite serious out-
comes. These findings suggest the early and long-term safe-
ty and efficacy of stenting versus CABG for unprotected 
LMCA disease in patients with or without DM. This notion 
is further supported by a recent study showing that the ad-
justed risks of death and of the composite (death, Q-wave 
MI, or stroke) were similar in diabetic patients who received 
DES and those who underwent CABG, and that diabetes 
had a minimal prognostic impact on the long-term treatment 
effects in patients who underwent DES or CABG.40 It should 
be noted that not only non-diabetic but also diabetic patients 
treated with DES show higher rates of TVR as compared to 
those treated with CABG. Effectiveness and durability are 
concerns related to stenting in coronary atherosclerotic ste-
nosis, as is safety with regards to potential in-stent thrombo-
sis in DES implantation. Although one angiographic study 
that lasted for up to four years suggested that DES implanta-
tion has a low in-stent restenosis rate,41 most other studies 
have suggested that it has a high TVR rate,3,21 and it is not 
known whether PCI with DESs further increases the TVR 
rate. In CABG, the grafts usually bypass the proximal epi-
cardial coronary segment, in which more obstructive lesions 
occur and progress;42 the alternative route provided by the 
surgery can perfuse the distal myocardial territory,8 thus pro-
tecting, to some degree, against progressive atherosclerosis.
There are inherent limitations to our study. First, this was 
a single-center retrospective study; therefore, the results are 
not adequate to draw definite wide-ranging conclusions. Sec-
ond, there were baseline clinical differences between the 
study groups, highlighting the inevitable bias related to pa-
tient selection. This was similar to previous studies of clini-
cal outcomes following CABG and PCI for LMCA steno-
sis.43,44 Patients who underwent CABG had more multi-
vessel lesions and a lower Ontario score and cardiac output, 
while patients who underwent PCI had a higher incidence 
of poorly controlled diabetes and a higher prevalence and 
family history of cardiovascular disease with previous cor-
onary bypass grafting. Third, the number of study patients 
was too small to generalize our results to all diabetic pa-
tients with LMCA lesions.
In conclusion, these results provide new information re-
garding the safety and effectiveness of DES implantation in 
diabetic patients with LMCA lesions. These data highlight 
tients.26 DES implantation has recently been shown to be safe 
with regard to acute and midterm complications and the pre-
vention of restenosis in patients with unprotected LMCA ste-
nosis.10 More recent observational studies have shown simi-
lar mortality rates and similar risks of major cardiac and 
cerebrovascular events in both patients receiving DESs and 
those undergoing CABG.27,28 These studies have all been 
limited by a lack of consideration of coronary disease risk 
factors (including diabetes and hypertension), a limited du-
ration of follow-up, and selective use of PCI in patients con-
sidered to be poor candidates for CABG.
Despite endeavors to decrease in-stent restenosis after 
LMCA intervention with BMSs, such as by the use of ag-
gressive debulking atherectomy, the restenosis rate remains 
high at 20% to 30%.26,29,30 Generally, before the development 
of the DES, BMS-related in-stent restenosis was widely rec-
ognized as the most important reason for which bypass sur-
gery was the first choice for treating LMCA stenosis. On 
the other hand, DES implantation for LMCA lesions has re-
cently been shown to reduce rates of in-stent restenosis and 
the rates of target-vessel revascularization in LMCA lesions, 
or both.10,11 However, recent observational studies have re-
ported that the restenosis rate with DESs was still higher in 
patients with DM than in those without DM.31 The FRE-
DOM trial was designed to define the optimal revascular-
ization strategy for diabetic patients with multi-vessel coro-
nary disease.32 Here, we observed that the rate of TVR was 
higher in diabetic patients who underwent PCI than in pa-
tients undergoing CABG, although we did not evaluate the 
impact of diabetic coronary risk factors on in-stent resteno-
sis. Given the limitations in the trials to date and the inher-
ent risk of DES restenosis, results from randomized trials 
are still needed to definitively establish the role of DES im-
plantation in place of the reference treatment surgery for di-
abetic patients with LMCA disease.
A number of single- and multi-center cohort studies have 
shown that DES stenting is similar to CABG for patients 
with unprotected LMCA disease in terms of short- and long-
term mortality and rates of death, Q-wave MI, or stroke.33-36 
Notably, Sheiban and other groups reported that EDS stents 
showed favorable early and long-term results in selected di-
abetic and nondiabetic individuals undergoing PCI for un-
protected LMCA disease.37,38 Furthermore, recent subgroup 
analyses by Banning and colleagues suggest that the com-
posite safety end point (death/stroke/MI) is comparable be-
tween the two treatment options for both diabetic and nondi-
abetic patients, even though the one-year major adverse DES vs. CABG for Diabetic Patients with LMCA Disease
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